Recent Advances in Hormonal Contraceptives for Women
DOI:
https://doi.org/10.37285/ijpsn.2008.1.3.1Abstract
Currently, Contraceptive agents play a key role in family planning in India. Hormonal contraception is the marketed most common birth control option in women. An estimated 100 million women throughout the world use hormonal contraceptives for prevention of pregnancy. This article briefly describes the recent advances in hormonal contraceptive strategies that may minimize side effects while optimizing effective contraception. There are four types of hormonal contraceptive agents available for birth control. They include oral contraceptives pills (combined and mini-pills), contraceptive patches, hormonal implants, intrauterine devices and hormone injection agents. Oral contraceptives (OCs) are among the most widely used agents because they are highly effective when used properly. Generally, OCs are designed to simulate the 28 days of the menstrual cycle by daily intake of steroid hormones consisting of an estrogen and/or a progesterone. The primary mechanism underlying OC action is inhibition of ovulation. This action is achieved using a variety of OCs with substantially different components, doses, and side effect profile. Two types of OC pills are widely available: combination pills; and progesterone only pills. The combined daily OC pill is composed of low dose of synthetic estrogen and progesterone. They are usually taken for 21 days with a 7 day gap during which menstruation-like bleeding occurs. Recently, there are several new OCs that have been approved to minimize the frequency and/or extent of breakthrough bleeding while achieving reliable means of contraception for the avoidance of unplanned pregnancies.
Downloads
Metrics
Keywords:
Oral contraceptives, estrogen, progesterone, birth control, drug interactions, epilepsy
Downloads
Published
How to Cite
Issue
Section
References
Anderson FD, Gibbons W, Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. Am J Obstet Gynecol 195: 92-96 (2006).
Andrist LC, Arias RD, Nucatola D, et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception. 70: 359-363 (2004).
Back DJ, Grimmer SFM, Orme MLE, Proudlove C., Mann RD, Breckenridge AM. Evaluation of committee on safety of medicine yellow card reports on oral contraceptive-drugs interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 25: 527-532 (1980).
Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 30: 892-896 (1990).
Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 46 (Suppl. 9): 117-124 (2005).
Crawford P. Family planning and contraceptive choice. In: Women with epilepsy: A handbook of treatment issues. Morrell MJ, Flynn K L, eds. Cambridge University Press. 197-202 (2003).
Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 16: 263-272 (2002).
Drey EA, Darney PD. Recent developments in hormonal contraception. Rev Endocr Metab Disord 3: 257-265 (2002).
Fairgrieve SD, Jackson M, Jonas P, Walshaw D, White K, Montgomery TL, Burn J, Lynch SA. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 321: 674-675 (2000).
Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 40: 783-7 (1999).
Guengerich FP. Mechanism-based inactivation of human liver microsomal cytochrome P-450 3A4 by gestodene. Chem Res Toxicol 3: 363-371 (1990).
Glasier A. Contraception, In: DeGroot LJ and Jameson JL (eds.): Endocrinology, 5th edition, Philadelphia: Elsevier Saunders, pp-2993-3003 (2006).
Harden CL and Leppik I. Optimizing therapy of seizures in women who use oral contraceptives. Neurology 67(Suppl 4):S56-S58 (2006).
Hatcher RA, Nelson A. Combined Hormonal Contraceptive Methods. In: Hatcher RA, ed. Contraceptive Technology, 18th Edn, Ardent Media, New York, pp-391-460 (2004).
Kaneko S. Pregnancy and quality of life in women with epilepsy. Clin Therap 20 (Suppl A): A30- A47 (1998).
Kaunitz AM. Beyond the pill: New data and options in hormonal and intrauterine contraception. Am J Obstet Gynec 192: 998-1004 (2005).
Lin HL, Kent UM, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 3A4 by17α-ethynylestradiol: Evidence for heme destruction and covalent binding to protein. J Pharm Exp Therap 301: 160-167 (2002).
Oakeley P. Choices of contraception. Curr Obstet Gynecol 14: 68-71 (2004).
O’Brien MD, Guillebaud J. Contraception for women with epilepsy. Epilepsia 47: 1419-1422 (2006).
Reddy DS. Perimenstrual catamenial epilepsy. Women’s Health 3: 195-206 (2007).
Sarlis NJ, Gourgiotis L. Hormonal effects on drug metabolism through the CYP system: perspectives on their potential significance in the era of pharmacogenomics. Curr Drug Targets Immune Endocr Metabol Disord 5: 439-48 (2005).
Sabers A, Öhman I, Christensen J and Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 61: 570-571 (2003).
Teal SB, Ginosar DM. Contraception for women with chronic medical conditions. Obstet Gynecol Clin N Am 34: 113-126 (2007).
Terrie YC. Extended Regimens—The New Standard for OCs? Pharmacy Times, June issue (2008).
Wilbur K and Ensom MHH. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin Pharmacokinet 38: 355-365 (2000).
